Search
On July 18, the National Medical Products Administration's official website announced the approval of Zhengxiang Pharmaceutical's groundbreaking oral antiviral flu drug, Maseniloxavir Tablets (trade name: Jikeshu), for market distribution. This medication is specifically designed for previously healthy adults with uncomplicated influenza A and B, demonstrating efficacy against both influenza A and B viruses, as well as highly pathogenic avian influenza viruses. As a new-generation inhibitor of polymerase acidic protein (PA) endonuclease, Jikeshu boasts broad-spectrum antiviral properties, requiring only a single dose for the entire course of treatment and offering swift fever reduction. This marks a significant advancement in the innovative development of antiviral flu medications in China.
-
C114 Communication Network -
Communication Home
